•  
  •  
 

Subject Area

Obstetrics and Gynecology

Article Type

Original Study

Abstract

Objective The aim was to study the relationship between baseline choroidal thickness and functional improvement in central retinal vein occlusion (CRVO) patients receiving antivascular endothelial growth factor (VEGF) therapy. Background CRVO is one of the most common vascular diseases of the retina that seriously affect visual acuity. Design Prospective study. Patients and methods Forty eyes of 40 patients with CRVO were included. All patients received anti-VEGF treatment (Ranibizumab) three injections 1 month apart. Enhanced depth imaging optical coherence tomography was used to evaluate choroidal thickness and macular thickness at baseline and after treatment. Also, best-corrected visual acuity was documented before and after treatment as a sign of functional improvement. Results Forty eyes of 40 patients with CRVO were included. Patients were classified into two groups according to their improvement in visual acuity: the responder group in whom visual acuity gain greater than or equal to two lines and the nonresponder group in whom visual acuity gain less than two lines. Baseline choroidal thickness in CRVO eyes (259 ± 37.9 μm) was thicker than in their fellow eye (202.5 ± 21.8 μm) (P = 0.001). Mean choroidal thickness at baseline for functional responders (259.2 ± 37.9 μm) was greater than that of nonresponders (224.9 ± 33.6 μm) (P = 0.005). On multivariate analysis a thicker baseline choroidal thickness (<237 μm) was found to be a positive indicator for visual improvement (odds ratio = 2.45; P = 0.025), Also, age (<60 years old) was a positive indicator for visual improvement (odds ratio = 2.39; P = 0.036). Conclusion Initial choroidal thickness and the age of patients can be used as a prognostic indicator for functional improvement in CRVO patients receiving anti-VEGF treatment.

Download

Share

COinS